Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toni K. Choueiri, M.D.

Co-Author

This page shows the publications co-authored by Toni Choueiri and Alexander Cole.
Connection Strength

2.211
  1. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.219
  2. Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? Prostate Cancer Prostatic Dis. 2019 12; 22(4):593-599.
    View in: PubMed
    Score: 0.214
  3. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.210
  4. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREĀ® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.189
  5. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.174
  6. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
    View in: PubMed
    Score: 0.166
  7. Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24.
    View in: PubMed
    Score: 0.060
  8. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.057
  9. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.056
  10. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
    View in: PubMed
    Score: 0.054
  11. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
    View in: PubMed
    Score: 0.054
  12. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.053
  13. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.053
  14. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
    View in: PubMed
    Score: 0.053
  15. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.052
  16. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
    View in: PubMed
    Score: 0.052
  17. Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
    View in: PubMed
    Score: 0.052
  18. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urol Oncol. 2018 09; 36(9):400.e15-400.e22.
    View in: PubMed
    Score: 0.051
  19. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.051
  20. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774.
    View in: PubMed
    Score: 0.050
  21. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.050
  22. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.049
  23. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 06; 199(6):1417-1425.
    View in: PubMed
    Score: 0.049
  24. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.049
  25. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
    View in: PubMed
    Score: 0.048
  26. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.